MEIRAGTX HOLDINGS PLC (MGTX)
KYG596651029 - Common Stock
MEIRAGTX HOLDINGS PLC
NASDAQ:MGTX (10/18/2024, 8:00:02 PM)
After market: 6.2 +0.06 (+0.98%)6.14
+0.2 (+3.37%)
Company Profile
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 402 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Company Info
MEIRAGTX HOLDINGS PLC
450 E 29th St Fl 15
New York City NEW YORK 10016
P: 16464902965
CEO: Alexandria Forbes
Employees: 387
Website: https://meiragtx.com/
MGTX News
5 days ago - ChartmillThe market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
6 days ago - MeiraGTxMeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease11 days ago - MeiraGTxMeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience ConferenceResults indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency
11 days ago - MeiraGTxMeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience ConferenceResults indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency...
2 months ago - InvestorPlaceMGTX Stock Earnings: MeiraGTx Hldgs Misses EPS, Misses Revenue for Q2 2024MGTX stock results show that MeiraGTx Hldgs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
2 months ago - BusinessInsiderMGTX Stock Earnings: MeiraGTx Hldgs Misses EPS, Misses Revenue for Q2 2024InvestorPlace - Stock Market News, Stock Advice & Trading Tips MeiraGTx Hldgs (NASDAQ:MGTX) just reported results for the second quarter of 20...
MGTX Twits
Here you can normally see the latest stock twits on MGTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
